Cited by 284Global Cancer Incidence and ScreeningDigital Radiography and Breast ImagingHealth Systems, Economic Evaluations, Quality of Life

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer: A Life-Table Model

Open access

Pashayan, Nora, Morris, Steve, Gilbert, Fiona J., Pharoah, Paul D. P.·2018·JAMA Oncology

DOI 10.1001/jamaoncol.2018.1901PMC PMC6230256

Open this paper in CoChat — free account Open PDF

Abstract

Importance: The age-based or "one-size-fits-all" breast screening approach does not take into account the individual variation in risk. Mammography screening reduces death from breast cancer at the cost of overdiagnosis. Identifying risk-stratified screening strategies with a more favorable ratio of overdiagnoses to breast cancer deaths prevented would improve the quality of life of women and save resources. Objective: To assess the benefit-to-harm ratio and the cost-effectiveness of risk-stratified breast screening programs compared with a standard age-based screening program and no screening. Design, Setting, and Population: A life-table model was created of a hypothetical cohort of 364 500 women in the United Kingdom, aged 50 years, with follow-up to age 85 years, using (1) findings of the Independent UK Panel on Breast Cancer Screening and (2) risk distribution based on polygenic risk profile. The analysis was undertaken from the National Health Service perspective. Interventions: The modeled interventions were (1) no screening, (2) age-based screening (mammography screening every 3 years from age 50 to 69 years), and (3) risk-stratified screening (a proportion of women aged 50 years with a risk score greater than a threshold risk were offered screening every 3 years until age 69 years) considering each percentile of the risk distribution. All analyses took place between July 2016 and September 2017. Main Outcomes and Measures: Overdiagnoses, breast cancer deaths averted, quality-adjusted life-years (QALYs) gained, costs in British pounds, and net monetary benefit (NMB). Probabilistic sensitivity analyses were used to assess uncertainty around parameter estimates. Future costs and benefits were discounted at 3.5% per year. Results: The risk-stratified analysis of this life-table model included a hypothetical cohort of 364 500 women followed up from age 50 to 85 years. As the risk threshold was lowered, the incremental cost of the program increased linearly, compared with no screening, with no additional QALYs gained below 35th percentile risk threshold. Of the 3 screening scenarios, the risk-stratified scenario with risk threshold at the 70th percentile had the highest NMB, at a willingness to pay of £20 000 (US $26 800) per QALY gained, with a 72% probability of being cost-effective. Compared with age-based screening, risk-stratified screening at the 32nd percentile vs 70th percentile risk threshold would cost £20 066 (US $26 888) vs £537 985 (US $720 900) less, would have 26.7% vs 71.4% fewer overdiagnoses, and would avert 2.9% vs 9.6% fewer breast cancer deaths, respectively. Conclusions and Relevance: Not offering breast cancer screening to women at lower risk could improve the cost-effectiveness of the screening program, reduce overdiagnosis, and maintain the benefits of screening.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1001/jamaoncol.2018.1901

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The benefits and harms of breast cancer screening: an independent review
Marmot, M. G. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61611-0 · Cited by 1,495
Association analysis identifies 65 new breast cancer risk loci
Michailidou, K., Lindström, S., Dennis, J., Beesley, J., Hui, S., Kar, S., Lemaçon, A., Soucy, P., Glubb, D. M., Rostamianfar, A., et al. (2017) · Nature · doi:10.1038/nature24284 · Cited by 1,380
Untitled work
Higgins (2002) · doi:10.1002/(issn)1097-0258 · Cited by 1,248
Polygenic susceptibility to breast cancer and implications for prevention
Pharoah, P. D. P., Antoniou, A. C., Bobrow, M., Zimmern, R. L., Easton, D. F., & Ponder, B. A. J. (2002) · Nature Genetics · doi:10.1038/ng853 · Cited by 898
Self-citation
Breast Cancer Risk From Modifiable and Nonmodifiable Risk Factors Among White Women in the United States
Maas, P., Barrdahl, M., Joshi, A. D., Auer, P. L., Gaudet, M. M., Milne, R. L., Schumacher, F. R., Anderson, W. F., Check, D., Chattopadhyay, S., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.1025 · Cited by 373
Personalizing Mammography by Breast Density and Other Risk Factors for Breast Cancer: Analysis of Health Benefits and Cost-Effectiveness
Schousboe, J. T., Kerlikowske, K. M., Loh, A., & Cummings, S. R. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-1-201107050-00003 · Cited by 317
Estimation of mean sojourn time in breast cancer screening using a Markov chain model of both entry to and exit from the preclinical detectable phase
Duffy, S. W., Chen, H., Tabár, L. K., & Day, N. E. (1995) · Statistics in Medicine · doi:10.1002/sim.4780141404 · Cited by 208
Polygenic susceptibility to prostate and breast cancer: implications for personalised screening
Pashayan, N., Duffy, S. W., Chowdhury, S., Dent, T., Burton, H., Neal, D. E., Easton, D. F., Eeles, R. A., & Pharoah, P. D. P. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.118 · Cited by 160
Self-citation
Improvement in risk prediction, early detection and prevention of breast cancer in the NHS Breast Screening Programme and family history clinics: a dual cohort study
Evans, D. G., Astley, S., Stavrinos, P., Harkness, E. F., Donnelly, L. S., Dawe, S., Jacob, I., Harvie, M., Cuzick, J. M., Brentnall, A. R., et al. (2016) · Programme Grants for Applied Research · doi:10.3310/pgfar04110 · Cited by 153
Cost-Effectiveness and Harm-Benefit Analyses of Risk-Based Screening Strategies for Breast Cancer
Vilaprinyó, E., Forné, C., Carles-Lavila, M., Sala, M., Pla, R., Castells, X., Domingo, L., Rué, M., & the Interval Cancer (INCA) Study Group (2014) · PLoS ONE · doi:10.1371/journal.pone.0086858 · Cited by 142

Flagged first, then by citations

Show all 25 references

Research works printed but not linked: 1

Dent, 2014, Stratified Screening for Cancer: Recommendations and Analysis From the COGS Project

Sorted by citations

Items 201–284 of 284

Risk Stratified Breast Cancer Screening: Early Outcomes and Psychological Impact from PRSONAL – a Randomized Clinical Trial
Pedersen, L. H., Bigaard, J., Vejborg, I., Kamstrup, P. R., Andersen, B., Yang, X., Ficorella, L., Dennis, J., Antoniou, A. C., Flyger, H., et al. (2026) · The Breast · doi:10.1016/j.breast.2026.104743 · Cited by 3
Risk-stratified cancer screening: A consensus-based conceptual framework from EUCanScreen
Rossi, P. G., Senore, C., Giordano, L., Véron, L., Haddad, T., Guida, A., Vicentini, M., Leoni, F., Bonvicini, L., Colombo, C., et al. (2026) · European Journal of Cancer · doi:10.1016/j.ejca.2026.116746 · Cited by 3
Cost-effectiveness of genetic risk-stratified screening for breast cancer in Taiwan
Hou, Y., Lin, F., & Shao, Y. J. (2025) · The Breast · doi:10.1016/j.breast.2025.104566 · Cited by 3
Errors in the Calculation Used to Estimate Number of Overdiagnoses in Study of Risk-Stratified Screening for Breast Cancer
(2022) · JAMA Oncology · doi:10.1001/jamaoncol.2021.7316 · Cited by 3
Reproductive history differs by molecular subtypes of breast cancer among women aged ≤ 50 years in Scotland diagnosed 2009–2016: a cross-sectional study
Chitkara, A., Mesa‐Eguiagaray, I., Wild, S. H., Hall, P. S., Cameron, D., Sims, A. H., & Figueroa, J. D. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06721-1 · Cited by 4
Promote Community Engagement in Participatory Research for Improving Breast Cancer Prevention: The P.I.N.K. Study Framework
Franchini, M., Pieroni, S., Denoth, F., Scalese, M., Colasante, E., Salvatori, M., Anastasi, G., Frontignano, C. K., Dogliotti, E., Vidali, S., et al. (2022) · Cancers · doi:10.3390/cancers14235801 · Cited by 3
Polygenic risk scores for genomics and population screening
Perrott, S. L., & Kar, S. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01689-1 · Cited by 3
Polygenic Risk Scores in Breast Cancer
Mina, L. A., & Arun, B. (2019) · Current Breast Cancer Reports · doi:10.1007/s12609-019-00320-8 · Cited by 3
Precision Breast Cancer Screening with a Polygenic Risk ScorePreprint
Tasa, T., Puustusmaa, M., Tõnisson, N., Kolk, B., & Padrik, P. (2020) · medRxiv · doi:10.1101/2020.08.17.20176263 · Cited by 3
Supplemental Optoacoustic Imaging of Breast Masses: A Cost-Effectiveness Analysis
Ozcan, B. B., Xi, Y., & Doğan, B. E. (2023) · Academic Radiology · doi:10.1016/j.acra.2023.08.042 · Cited by 3
Functional partial least squares with censored outcomes: Prediction of breast cancer risk with mammogram images
Jiang, S., Cao, J., & Colditz, G. A. (2024) · The Annals of Applied Statistics · doi:10.1214/23-aoas1822 · Cited by 2
Considering Clinical Implementation of Polygenic Scores in Hereditary Cancer Risk Assessment: Recipients’ Perspectives on Influencing Factors and Strategies
Purvis, R., Taylor, N., James, P. A., Young, M., & Forrest, L. E. (2025) · Patient · doi:10.1007/s40271-025-00747-5 · Cited by 2
Stemming the Rising Tide of Early-Onset Cancers: Research Gaps and Public Health Actions
Terry, M. B., Tehranifar, P., & Kehm, R. D. (2025) · Annual Review of Public Health · doi:10.1146/annurev-publhealth-082024-063125 · Cited by 3
Implementation of a net benefit parameter in ROC curve decision thresholds for AI-powered mammography screening
Pamova, A. P., Vasilev, Y. A., Bobrovskaya, T. M., Vladzymyrskyy, A. V., Omelyanskaya, O. V., & Arzamasov, K. M. (2025) · Frontiers in Big Data · doi:10.3389/fdata.2025.1690955 · Cited by 2
Canadian Women’s Attitudes Toward Receiving Personalized Breast Cancer Risk Information: Insights From the PERSPECTIVE I&I Project
Brooks, J. D., Blackmore, K. M., Ngo, N. N. M., Walker, M. J., Chang, A., Lambert-Côté, L., Turgeon, A., Lofters, A., Nabi, H., Antoniou, A. C., et al. (2025) · Clinical Breast Cancer · doi:10.1016/j.clbc.2025.12.009 · Cited by 2
Self-citation
Risk Models to Predict Screen-Detected and Interval Breast Cancers in Population Mammography Screening Participants
Noguchi, N., Teixeira-Pinto, A. M., Marinovich, M. L., Louw, D. C., Wylie, E. J., & Houssami, N. (2025) · Cancers · doi:10.3390/cancers17050810 · Cited by 2
Overestimation of the Benefit-to-Harm Ratio of Risk-Based Mammography Screening in the United Kingdom
Autier, P. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.6501 · Cited by 2
Prognostic value of prior malignancy history in stage I differentiated thyroid cancer: a SEER-based study
Wang, Y., Li, S., Xu, F., & Hao, Q. (2023) · Translational Cancer Research · doi:10.21037/tcr-22-2232 · Cited by 2
Why a randomized melanoma screening trial may be a good idea
Cust, A. E., Aitken, J. F., Baade, P. D., Whiteman, D. C., Soyer, H. P., & Janda, M. (2018) · British Journal of Dermatology · doi:10.1111/bjd.17089 · Cited by 2
Evaluation of a Risk-Stratified National Breast Screening Programme in the United Kingdom: An updated cost-effectiveness analysisPreprint
Wright, S. J., Rogers, G., Gray, E., Donten, A., McWilliams, L., French, D., Evans, D. G., & Payne, K. (2024) · medRxiv · doi:10.1101/2024.04.16.24305897 · Cited by 2
The current situation of screening mammography and toward riskstratified breast cancer screening in Japan
Uematsu, T. (2023) · Nihon Nyugan Kenshin Gakkaishi (Journal of Japan Association of Breast Cancer Screening) · doi:10.3804/jjabcs.32.17 · Cited by 1
Advanced Versus Invasive Breast Cancer Risk in a Screening Population: Implications for Risk-based Prevention and Screening Strategies
Sprague, B. L., Gard, C. C., Chen, S., Tice, J. A., Tosteson, A. N. A., Perry, H., Lee, C. I., Miglioretti, D. L., & Kerlikowske, K. M. (2026) · Journal of General Internal Medicine · doi:10.1007/s11606-026-10237-5 · Cited by 1
Health Economic Evaluations of Breast Cancer Screening Strategies: A Systematic Review Focusing on Methodology and Quality Assessment
Pham, T. H., Braak, S., van der Werf, S., Khoirunnisa, S. M., Pan, X., Pfob, A., Wondimu, A., van der Schans, J., Postma, M. J., van Asselt, A. D. I., et al. (2026) · Applied Health Economics and Health Policy · doi:10.1007/s40258-026-01049-z · Cited by 1
Breast cancer risk coordinators: Artificial intelligence–based density measurement and Mullerian-inhibiting substance
Pedük, Ş., Sarıkaya, S., & Tekin, M. (2022) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-022-03187-4 · Cited by 1
Risk-Stratified Breast Cancer Screening
Uematsu, T. (2023) · Health Evaluation and Promotion · doi:10.7143/jhep.50.284 · Cited by 1
Early diagnostics of aggressive cancers: alliance of physicians, technologies and artificial intelligence
Rumyantsev, P. O. (2023) · Diagnostic radiology and radiotherapy · doi:10.22328/2079-5343-2023-14-2-7-14 · Cited by 1
Cancer Epidemiology
Boffetta, P., & Collatuzzo, G. (2023) · Springer eBooks · doi:10.1007/978-1-4614-6625-3_36-1 · Cited by 2
A structured process for the validation of a decision-analytic model: application to a cost-effectiveness model for risk-stratified national breast screening
Wright, S. J., Gray, E., Rogers, G., Donten, A., & Payne, K. (2024) · Applied Health Economics and Health Policy · doi:10.1007/s40258-024-00887-z · Cited by 1
Determining risk‐adapted starting age and interval for breast cancer screening based on reproductive and hormonal factors
Hoang, T., Lee, J., Jung, S., & Kim, J. (2024) · International Journal of Cancer · doi:10.1002/ijc.35265 · Cited by 1
Overestimation of the Benefit-to-Harm Ratio of Risk-Based Mammography Screening in the United Kingdom—Reply
Pashayan, N., & Pharoah, P. D. P. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.6504 · Cited by 1
Self-citation
Preventive population genomics: The model of BRCA related cancers
Reisel, D., Baran, C., & Manchanda, R. (2021) · Advances in genetics · doi:10.1016/bs.adgen.2021.08.001 · Cited by 1
Polygenic Risk-Tailored Screening for Prostate Cancer: A Benefit–Harm and Cost-Effectiveness Modelling Study
Callender, T., Emberton, M., Stephen Morris, A., Eeles, R. A., Kote‐Jarai, Z., Pharoah, D. P. P., & Pashayan, N. (2021) · doi:10.1201/9781003180449-19 · Cited by 1
Self-citation
Risk stratification in breast screening: A word of caution
Duffy, S. W. (2018) · Journal of Medical Screening · doi:10.1177/0969141318813387 · Cited by 1
Population-level breast screening: how to salvage the concept?
Clift, A. K. (2020) · Journal of the Royal Society of Medicine · doi:10.1177/0141076820910317 · Cited by 1
Integrating a Polygenic Risk Score for Coronary Artery Disease as a Risk Enhancing Factor in the Pooled Cohort Equation is Cost-effective in a US Health SystemPreprint
Mujwara, D., Henno, G., Vernon, S. T., Peng, S., Domenico, P. D., Schroeder, B. E., Busby, G., Figtree, G. A., & Bottà, G. (2021) · medRxiv · doi:10.1101/2021.06.21.21259210 · Cited by 1
Integrating genome-wide polygenic risk scores and non-genetic risk to predict colorectal cancer diagnosis: a cohort study in UK BiobankPreprint
Briggs, S., Law, P., East, J. E., Wordsworth, S., Dunlop, M. G., Houlston, R. S., Hippisley‐Cox, J., & Tomlinson, I. P. M. (2021) · medRxiv · doi:10.1101/2021.09.22.21263962 · Cited by 1
Use of repeated mammograms to evaluate risk of breast cancer: a systematic review of methods used in the literaturePreprint
Anandarajah, A., Chen, Y., Stoll, C. R. T., Hardi, A., Jiang, S., & Colditz, G. A. (2021) · medRxiv · doi:10.1101/2021.11.10.21266200 · Cited by 1
Validation of a decision-analytic model for the cost-effectiveness analysis of a risk-stratified National Breast Screening Programme in the United KingdomPreprint
Wright, S. J., Gray, E., Rogers, G., Donten, A., & Payne, K. (2022) · medRxiv · doi:10.1101/2022.12.05.22283099 · Cited by 1
An implementation study of the service model for genetic risk-based stratified breast cancer screening – Estonian results of the BRIGHT projectPreprint
Tamm, M., Padrik, P., Ojamaa, K., Paas, A., Lepland, A., Kruuv-Käo, K., Leitsalu, L., Sõber, S., Roht, L., Pajusalu, S., et al. (2024) · medRxiv · doi:10.1101/2024.10.22.24315198 · Cited by 1
Adapting the BOADICEA breast and ovarian cancer risk models for the ethnically diverse UK populationPreprint
Ficorella, L., Yang, X., Mavaddat, N., Carver, T. J., Hassan, H., Dennis, J., Tyrer, J. P., Ho, W.-K., Teo, S., Hartman, M., et al. (2025) · medRxiv · doi:10.1101/2025.02.14.25322307 · Cited by 1
Self-citation
Targeted breast screening could reduce overdiagnosis and be more cost effective, study finds
Thornton, J. (2018) · BMJ · doi:10.1136/bmj.k3009
High-Value Health Care: Perspectives from the Sex- and Gender-based Care Lens
Mitchell, J. L. (2020) · Springer eBooks · doi:10.1007/978-3-030-50695-7_2
Risk-stratified breast cancer screening
Uematsu, T. (2021) · Nihon Nyugan Kenshin Gakkaishi (Journal of Japan Association of Breast Cancer Screening) · doi:10.3804/jjabcs.30.39
Changes Reflecting Corrections to Related Article
(2022) · JAMA Oncology · doi:10.1001/jamaoncol.2021.7317
Is risk-stratified breast cancer screening a better option?
(2018) · PharmacoEconomics & Outcomes News · doi:10.1007/s40274-018-5098-5
Advances in Breast Cancer Screening: Precision, Imaging, and Harms
Toi, M., Kataoka, M., Velaga, R., Benson, J. R., Takada, M., & Jatoi, I. (2023) · Springer eBooks · doi:10.1007/978-981-19-7630-8_1
Assessing the cost-effectiveness of waiting list reduction strategies for a breast radiology department: a real-life case study
Fanizzi, A., Graps, E. A., Bavaro, D. A., Farella, M., Bove, S., Campobasso, F., Comes, M. C., Cristofaro, C., Forgia, D. L., Milella, M., et al. (2023) · BMC Health Services Research · doi:10.1186/s12913-023-09447-y
Cost Considerations
Kane, G. C. (2023) · Springer eBooks · doi:10.1007/978-3-031-33596-9_20
A combined risk model shows viability for personalized breast cancer risk assessment in the Indonesian populationPreprint
Rabbani, B., Tanu, S. G., Ramanto, K. N., Audrienna, J., Aldila, F., Fernandez, E. A., Gonzàlez-Porta, M., Valeska, M. D., Haruman, J., Ulag, L. H., et al. (2023) · medRxiv · doi:10.1101/2023.09.22.23295602
Unpacking factors contributing to melanoma overdiagnosis: does polygenic risk play a role?
Smit, A. K., & Cust, A. E. (2023) · British Journal of Dermatology · doi:10.1093/bjd/ljad431
The benefit of adding polygenic risk scores, lifestyle factors, and breast density to family history and genetic status for breast cancer risk and surveillance classification of unaffected women from germline CHEK2 c.1100delC families
Schreurs, M. A. C., y Cajal, T. R., Adank, M. A., Collée, J. M., Hollestelle, A., van Rooij, J., Schmidt, M. K., & Hooning, M. J. (2024) · The Breast · doi:10.1016/j.breast.2024.103724
Radiation Dose
Tack, D. (2024) · Medical radiology · doi:10.1007/174_2024_504
Utilizing polygenic risk score for breast cancer risk prediction in a Taiwanese population
Lin, Y., Hung, C., Lin, G., Tsai, I.-C., Lum, C. Y., & Hsiao, T. (2024) · Cancer Epidemiology · doi:10.1016/j.canep.2024.102701
Awareness, attitude, and practice regarding breast self-examination among female employees working at Islamic Azad University, Zanjan branch in 2023
Kelachayeh, S. S. R., Razaghpour, H., Ahmadi, R., & Mohammadzadeh, M. (2024) · Preventive Care In Nursing and Midwifery Journal · doi:10.61186/pcnm.14.3.52
Transforming primary care through digital health technology
Lee, K. A. V., Kaplin, S. L., Glicksberg, B. S., & Krittanawong, C. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-15728-8.00021-5
Economic evaluation of personalised versus conventional risk assessment for women who have undergone testing for hereditary breast and ovarian cancer genes: a modelling study
Xi, Q., Fennell, N., Archer, S., Tischkowitz, M. D., Antoniou, A. C., & Stephen Morris, A. (2025) · Journal of Medical Genetics · doi:10.1136/jmg-2024-109948
A combined risk model shows viability for personalized breast cancer risk assessment in the Indonesian population: A case/control study
Rabbani, B., Tanu, S. G., Ramanto, K. N., Audrienna, J., Fernandez, E. A., Aldila, F., Gonzàlez-Porta, M., Valeska, M. D., Haruman, J., Ulag, L. H., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0321545
Is maximizing the promotion of breast cancer screening ethically and morally justifiable?
Zhang, H. (2025) · Asian Journal of Medical Humanities · doi:10.1515/ajmedh-2025-0005
Improving preventive screening efficiency: A population-based model of age-specific mammographic density for breast Cancer detection in Saudi Arabia
Alotaibi, S. (2025) · Preventive Medicine Reports · doi:10.1016/j.pmedr.2025.103321
Additional file 3 of Meta-analysis of diagnostic cell-free circulating microRNAs for breast cancer detection
Šehović, E., Urru, S., Chiorino, G., & Doebler, P. (2022) · Figshare · doi:10.6084/m9.figshare.20047290
Additional file 3 of Cost effectiveness analysis of a polygenic risk tailored breast cancer screening programme in Singapore
Wong, J. Z. Y., Chai, J. H., Yeoh, Y. S., Mohamed Riza, N. K., Liu, J., Teo, Y.-Y., Wee, H. L., & Hartman, M. (2021) · Figshare · doi:10.6084/m9.figshare.14478927
Additional file 1 of Attitudes towards risk-stratified breast cancer screening: a population-based survey among 5,001 Danish women
Loft, L. H., Pedersen, L. H., Bigaard, J., & Bojesen, S. E. (2024) · Figshare · doi:10.6084/m9.figshare.25440989
Additional file 1 of Development and validation of polygenic risk scores for prediction of breast cancer and breast cancer subtypes in Chinese women
Hou, C., Xu, B., Hao, Y., Yang, D., Song, H., & Li, J. (2022) · Figshare · doi:10.6084/m9.figshare.19556404
Additional file 2 of Cost effectiveness analysis of a polygenic risk tailored breast cancer screening programme in Singapore
Wong, J. Z. Y., Chai, J. H., Yeoh, Y. S., Mohamed Riza, N. K., Liu, J., Teo, Y.-Y., Wee, H. L., & Hartman, M. (2021) · Figshare · doi:10.6084/m9.figshare.14478924
Additional file 1 of Cost effectiveness analysis of a polygenic risk tailored breast cancer screening programme in Singapore
Wong, J. Z. Y., Chai, J. H., Yeoh, Y. S., Mohamed Riza, N. K., Liu, J., Teo, Y.-Y., Wee, H. L., & Hartman, M. (2021) · Figshare · doi:10.6084/m9.figshare.14478921
Additional file 1 of Cost-effectiveness of using artificial intelligence versus polygenic risk score to guide breast cancer screening
Mital, S., & Nguyen, H. V. (2022) · Figshare · doi:10.6084/m9.figshare.19728292
Additional file 2 of Attitudes towards risk-stratified breast cancer screening: a population-based survey among 5,001 Danish women
Loft, L. H., Pedersen, L. H., Bigaard, J., & Bojesen, S. E. (2024) · Figshare · doi:10.6084/m9.figshare.25441016
Additional file 1 of Predictive models of Alzheimer’s disease dementia risk in older adults with mild cognitive impairment: a systematic review and critical appraisal
Wang, X., Zhou, S., Ye, N., Li, Y., Pengjun, Z., Chen, G., & Hu, H. (2024) · Figshare · doi:10.6084/m9.figshare.26066110
Additional file 1 of Meta-analysis of diagnostic cell-free circulating microRNAs for breast cancer detection
Šehović, E., Urru, S., Chiorino, G., & Doebler, P. (2022) · Figshare · doi:10.6084/m9.figshare.20047284
Additional file 3 of Healthcare professionals’ views following implementation of risk stratification into a national breast cancer screening programme
Hawkins, R. L., McWilliams, L., Ulph, F., Evans, D. G., & French, D. (2022) · Figshare · doi:10.6084/m9.figshare.21321697
Additional file 1 of Healthcare professionals’ views following implementation of risk stratification into a national breast cancer screening programme
Hawkins, R. L., McWilliams, L., Ulph, F., Evans, D. G., & French, D. (2022) · Figshare · doi:10.6084/m9.figshare.21321691
Additional file 1 of European women’s perceptions of the implementation and organisation of risk-based breast cancer screening and prevention: a qualitative study
Rainey, L., van der Waal, D., Jervaeus, A., Donnelly, L. S., Evans, D. G., Hammarström, M., Hall, P., Wengström, Y., & Broeders, M. J. M. (2020) · Figshare · doi:10.6084/m9.figshare.12028350
Additional file 2 of Healthcare professionals’ views following implementation of risk stratification into a national breast cancer screening programme
Hawkins, R. L., McWilliams, L., Ulph, F., Evans, D. G., & French, D. (2022) · Figshare · doi:10.6084/m9.figshare.21321694
Dépistage personnalisé du cancer du sein : objectifs et perspectives
Balleyguier, C., Arfi, J., Véron, L., & Delaloge, S. (2026) · Imagerie de la Femme · doi:10.1016/j.femme.2026.01.001
Mammography and ultrasonography in breast cancer screening: Integrating genetic risk for personalized diagnostic strategies
Chen, R., Li, P., & Li, A. (2026) · Journal of Radiation Research and Applied Sciences · doi:10.1016/j.jrras.2026.102249
Net benefit of surveillance varies by hepatocellular carcinoma risk in patients with cirrhosis
Patel, A., Gavrila, E. I., Yekkaluri, S., Hoshida, Y., Hernáez, R., & Singal, A. G. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.101831
Development of a discrete event simulation model for health economic evaluation of interventions for patients with schizophrenia
Zhou, J. (2020) · doi:10.70675/d5d69c5azdaefz4c71z96a8z00e13384249d
Screening for Breast Cancer
Smit, F., Kaufman, J. S., & Chiolero, A. (2026) · JAMA · doi:10.1001/jama.2026.1266
Contribution of Risk Factors, Including Polygenic Score, to the Multifactorial Risk Assessment for the Implementation of Personalized Breast Cancer Screening: Insights from the PERSPECTIVE: Integration and Implementation Project
Yang, X., Usher‐Smith, J. A., Blackmore, K. M., Brooks, J. D., Bell, K. A., Carver, T. J., Chang, A., Chiquette, J., Easton, D. F., Eisen, A. F., et al. (2026) · Cancers · doi:10.3390/cancers18091482
Self-citation
Risk Stratification Tools for Thyroid Cancer: A Systematic Review of Models Combining Ultrasound, Cytology, and Clinical Risk Factors
Watts, E., Sattar, Z., Boelaert, K., & Sharma, N. (2026) · Thyroid · doi:10.1177/10507256261448300
Comparative 10-year performance of mammography artificial intelligence, polygenic, and clinical breast cancer risk models in the Kaiser Permanente Research Bank
Arasu, V. A., Gadgil, T., Rothstein, J. H., Alexeeff, S., Achacoso, N. S., Bhattacharya, A., Cord, J. B., Esserman, L. J., Galbraith, W. B., Gerstley, L. D., et al. (2026) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djag154 · Cited by 1
Implementing polygenic risk-based breast cancer screening across European health systems: insights from the BRIGHT project
del Vicario, M., Pons-Muzzo, L., Harkin, K., Assens, R. M. I., Lasebikan, T. O., Tõnisson, N., Padrik, P., Feldman, I., Sampaio, F., Costa, L. R., et al. (2026) · Frontiers in Health Services · doi:10.3389/frhs.2026.1829295
Evaluation of the impact of a third mammographic reading in the French population-based breast cancer screening program
Koivogui, A., SAIFI, S., RAZAFIJA, M., MENSAH, P., Bernoux, A., Chérel, P., & SELLIER, N. (2026) · Cancer Epidemiology · doi:10.1016/j.canep.2026.103188
Cost-effectiveness of mammography-based breast cancer screening in Jordan: a healthcare system perspective
Altawalbeh, S. M., Gharaibeh, M., Alothman, L., Wateska, A. R., & Smith, K. J. (2026) · Breast Cancer · doi:10.1007/s12282-026-01904-w

Authors: Pashayan, N., Morris, S., Gilbert, F. J., & Pharoah, P. D. P.
Affiliations: University College London (GB)
Department of Applied Health Research, University College London, London, England
University of Cambridge (GB)
Corresponding author: Pashayan, Nora
ORCID: Pashayan, Nora
Gilbert, Fiona J.
Pharoah, Paul D. P.
Venue: JAMA Oncology
Publisher: American Medical Association (AMA)
Published: 2018-11-01
Volume: 4
Issue: 11
Pages: 1504
ISSN: 2374-2437 (ISSN-L)
DOI: 10.1001/jamaoncol.2018.1901
PMC: PMC6230256
OpenAlex: W2829068939
Cited by: 284
References: 25
Citations by year: 2026: 15 · 2025: 32 · 2024: 35 · 2023: 31 · 2022: 48 · 2021: 49 · 2020: 31 · 2019: 35 · 2018: 8
FWCI: 11.53
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by
Locations: JAMA Oncology (publishedVersion, cc-by)
Europe PMC (PubMed Central) (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
Funders: Cancer Research UK (10119, 16561, C490/A16561, 26884, A16561)
National Institute for Health and Care Research (NF-SI-0515-10067)
Engineering and Physical Sciences Research Council (EP/P006485/1)
Topics: Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Digital Radiography and Breast Imaging
Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
Keywords: breast cancer screening, risk-stratified screening, mammography, overdiagnosis, cost-effectiveness, polygenic risk score, risk thresholds, breast cancer mortality, quality-adjusted life years, net monetary benefit, life table model, women aged 50-69, National Health Service, willingness-to-pay threshold
MeSH terms: Aged, Breast Neoplasms, Cost-Benefit Analysis, Female, Humans, Middle Aged, Risk Assessment, Early Detection of Cancer

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer: A Life-Table Model

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks